 |
 |
A very interesting analysis of the Spheramine trial halt from the Michael J Fox Foundation - July 10, 2008 NEWS IN CONTEXT: Titan Pharmaceuticals Halts Phase 2 Trial of Spheramine Following Disappointing Results "In the first week of July 2008, Titan Pharmaceuticals, Inc., announced that it would halt the Phase 2 trial of its symptomatic Parkinson’s therapy Spheramine. The announcement came in the wake of results showing that the experimental drug had failed to meet clinical endpoints outlined for the trial. Only one week earlier, the company had reported positive five-year data from its Phase 1 open-label trial of the same treatment. The Michael J. Fox Foundation spoke with David Standaert, MD, PhD, a member of the Executive Scientific Advisory Board of The Michael J. Fox Foundation, to gain a clearer understanding of the seemingly conflicting results, and what people with PD should take away from the news. Dr. Standaert is the John and Juanelle Strain Professor of Neurology and Director, Center for Neurodegeneration and Experimental Therapeutics, at the University of Alabama at Birmingham...." see http://www.michaeljfox.org/newsEvents_parkinsonsInTheNews_article.cfm?ID=369 ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn